{"name":"ANI Pharmaceuticals","slug":"ani","ticker":"ANIP","exchange":"NASDAQ","domain":"anipharmaceuticals.com","description":"ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.","hq":"Baudette, MN","founded":0,"employees":"970","ceo":"Nikhil Lalwani","sector":"Branded & Generic Pharma","stockPrice":79.75,"stockChange":-1.13,"stockChangePercent":-1.4,"marketCap":"$1.8B","metrics":{"revenue":923705984,"revenueGrowth":20.5,"grossMargin":60.8,"rdSpend":51664000,"netIncome":78337000,"cash":326060992,"dividendYield":0,"peRatio":20.4,"fiscalYear":"FY2019"},"revenueBreakdown":[],"timeline":[{"date":"1952-01-01","label":"Phenergan Vc W/ Codeine first approved","drug":"Phenergan Vc W/ Codeine","drugSlug":"phenylephrine-bitartrate","type":"approval","sentiment":"positive"},{"date":"1959-01-01","label":"Tenuate first approved","drug":"Tenuate","drugSlug":"diethylpropion","type":"approval","sentiment":"positive"},{"date":"1995-01-01","label":"Casodex first approved","drug":"Casodex","drugSlug":"bicalutamide","type":"approval","sentiment":"positive"},{"date":"1997-01-01","label":"Pandel first approved","drug":"Pandel","drugSlug":"hydrocortisone-probutate","type":"approval","sentiment":"positive"},{"date":"1998-01-01","label":"Atacand first approved","drug":"Atacand","drugSlug":"candesartan-cilexetil","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-12-31","label":"Vancocin Phase 3 readout (Osteomyelitis (Refractory))","drug":"Vancocin","drugSlug":"vancomycin","type":"phase3_readout","sentiment":"neutral"},{"date":"2035-11-06","label":"Vancocin patent expiry (Method of Use)","drug":"Vancocin","drugSlug":"vancomycin","type":"patent_expiry","sentiment":"negative"},{"date":"2035-11-06","label":"Vancocin patent expiry (Formulation)","drug":"Vancocin","drugSlug":"vancomycin","type":"patent_expiry","sentiment":"negative"},{"date":"2035-11-06","label":"Vancocin patent expiry (Formulation)","drug":"Vancocin","drugSlug":"vancomycin","type":"patent_expiry","sentiment":"negative"},{"date":"2035-11-06","label":"Vancocin patent expiry (Formulation)","drug":"Vancocin","drugSlug":"vancomycin","type":"patent_expiry","sentiment":"negative"},{"date":"2035-11-06","label":"Vancocin patent expiry (Formulation)","drug":"Vancocin","drugSlug":"vancomycin","type":"patent_expiry","sentiment":"negative"},{"date":"2027-06-01","label":"Xanax patent cliff ($100.0M at risk)","drug":"Xanax","type":"patent_expiry","sentiment":"negative"},{"date":"2028-06-01","label":"Lamictal patent cliff ($50.0M at risk)","drug":"Lamictal","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Casodex","genericName":"bicalutamide","slug":"bicalutamide","indication":"Metastatic Prostate Carcinoma","status":"marketed"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Phenergan Vc W/ Codeine","genericName":"PHENYLEPHRINE BITARTRATE","slug":"phenylephrine-bitartrate","indication":"Allergic conjunctivitis","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Vancocin","genericName":"vancomycin","slug":"vancomycin","indication":"Bacterial endocarditis","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Atacand","genericName":"CANDESARTAN CILEXETIL","slug":"candesartan-cilexetil","indication":"Chronic heart failure","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Pandel","genericName":"HYDROCORTISONE PROBUTATE","slug":"hydrocortisone-probutate","indication":"Other","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"Tenuate","genericName":"DIETHYLPROPION","slug":"diethylpropion","indication":"Obesity","status":"marketed"}]}],"pipeline":[{"name":"Casodex","genericName":"bicalutamide","slug":"bicalutamide","phase":"marketed","mechanism":"Casodex works by blocking the androgen receptor, a protein that helps prostate cancer cells grow.","indications":["Metastatic Prostate Carcinoma"],"catalyst":""},{"name":"Phenergan Vc W/ Codeine","genericName":"PHENYLEPHRINE BITARTRATE","slug":"phenylephrine-bitartrate","phase":"marketed","mechanism":"Alpha-1B adrenergic receptor","indications":["Allergic conjunctivitis","Allergic rhinitis","Common cold","Cough","Dilated pupil"],"catalyst":""},{"name":"Vancocin","genericName":"vancomycin","slug":"vancomycin","phase":"marketed","mechanism":"Alpha-2A adrenergic receptor, D-alanyl-D-alanine dipeptidase, UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase","indications":["Bacterial endocarditis","Bacterial septicemia","Clostridium difficile diarrhea","Diphtheroid Prosthetic Heart Valve Endocarditis","Infection due to Staphylococcus aureus"],"catalyst":""},{"name":"Atacand","genericName":"CANDESARTAN CILEXETIL","slug":"candesartan-cilexetil","phase":"marketed","mechanism":"Atacand blocks the action of angiotensin II, a hormone that constricts blood vessels, to lower blood pressure and improve heart function.","indications":["Chronic heart failure","Hypertensive disorder"],"catalyst":""},{"name":"Pandel","genericName":"HYDROCORTISONE PROBUTATE","slug":"hydrocortisone-probutate","phase":"marketed","mechanism":"Glucocorticoid receptor","indications":[],"catalyst":""},{"name":"Tenuate","genericName":"DIETHYLPROPION","slug":"diethylpropion","phase":"marketed","mechanism":"Sodium-dependent dopamine transporter","indications":["Obesity"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"ANI Pharmaceuticals reported its financial results for the fourth quarter and full year 2023, with revenue of $143.8 million and net income of $13.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"ANI Pharmaceuticals Announces Agreement to Acquire Certain Assets from Teva Pharmaceuticals","summary":"ANI Pharmaceuticals announced an agreement to acquire certain assets from Teva Pharmaceuticals, expanding its portfolio of generic pharmaceutical products.","drugName":"","sentiment":"positive"},{"date":"2023-08-15","type":"regulatory","headline":"ANI Pharmaceuticals Receives FDA Approval for Generic Version of Xanax","summary":"ANI Pharmaceuticals received FDA approval for its generic version of Xanax, a widely used medication for anxiety disorders.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxORWV5dzZpN1VVN0hiNU5vQnF1Y3R0ZFJscHJWV0RkMWRYYzlJLUsxSk95V0k0OXc3dzd4ZUVjRVBrcWtpTEN5V1lsbi0zb085YzhrdkVtV1FFcUF6YmIyUS11XzZJMkdiQmxESW4tN1MtMF9pUkdnX2xIQ0hxem14REt5eTVfM1JkUFl3NjU4eXRTQ1otdXk4cTZzOXZ1MWI3NUNnMmtMYWY0MmoxeUQ5aTRVQXl3WUtROXgtNXFjUQ?oc=5","date":"2026-04-08","type":"regulatory","source":"Stock Titan","summary":"A new generic version of Monoket reaches market after FDA approval - Stock Titan","headline":"A new generic version of Monoket reaches market after FDA approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQbTd2ZjZ5eFVWTUZWaTBHcVgtMUlRM1JjWGJoUmlIenVIRTkzRWt2QzdOUXBuRklNdGxjX2RHVjJPbWdyWGRmQVJxcWM1RE44MzhfRlEwOElyRnlhZ1hidHFkSXowMF9taW5WQ0NPdTNKYjJpbUJEdEp2OXh1ZDVQbm9kV0ZxZHBwY2VWY2cxRnhYdw?oc=5","date":"2026-04-08","type":"patent","source":"grafa.com","summary":"ANI Pharmaceuticals (ANIP) launches generic Monoket tablets - grafa.com","headline":"ANI Pharmaceuticals (ANIP) launches generic Monoket tablets","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-07","type":"trial","source":"simplywall.st","summary":"Did ILUVIEN’s NEW DAY Trial Publication Just Reframe ANI Pharmaceuticals' (ANIP) Retinal Franchise Narrative? - simplywall.st","headline":"Did ILUVIEN’s NEW DAY Trial Publication Just Reframe ANI Pharmaceuticals' (ANIP) Retinal Franchise Narrative?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNSkh0d2tPSnlKVHRHRjZxLVdvb2RrQkxMNS1nclRsVTAtbHVUX0xmTDRUdlo4RWNuM2tCWmRuWFprdUs0ZXFCeGhVRXJsLVNNcU1HaDlxQVJOd2F6eFRqbVRITU1rWHhDWGhiVlZoUndwR3V5cTNTTy1nMmtPSmpSQ21aNTZzQ3dVOUhsLU5udjR4QmoybFJRaGZLbE9Qc3dOaVNjX1psRzQxd20yWDRKRG84eDU?oc=5","date":"2026-04-07","type":"pipeline","source":"Kalkine Media","summary":"ANI Pharmaceuticals (NASDAQ:ANIP) Price Gap Sparks Nasdaq Futures Focus - Kalkine Media","headline":"ANI Pharmaceuticals (NASDAQ:ANIP) Price Gap Sparks Nasdaq Futures Focus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAJBVV95cUxNc2NJYk5zZW9GNU5Iek41cTc1WC12OXYzT0o0TDlqa0xBYThzSG9GOFpoV0lfUUU1RlVXdTFpNW5oMklNUE8wdlZ6dWZzRUNkZWVaSUlEYTZMVlMwdHdrSWVsNzdiYjgyRUFBNFd2dno5UmJrY2VyWno5VHJSYWRFdU0tU1RJQlQyelY0X2pFc2tsSXlLU3NPZDlObGQ2a1MybXpZZGluTVVsN0Njc0laMXdZMi05QzBrS0x1R1I5Q3pUektzM1plRFZKb2hrWWktbmdmdEtUZnpJSGZXa2FaV1M1ZVBwNFJPNTZ4ME1EVGNrWUEteHJDWURkcVB0OGhoelFLTA?oc=5","date":"2026-04-07","type":"pipeline","source":"The Globe and Mail","summary":"Artivion, ANI Pharmaceuticals, and Privia Health Shares Are Soaring, What You Need To Know - The Globe and Mail","headline":"Artivion, ANI Pharmaceuticals, and Privia Health Shares Are Soaring, What You Need To Know","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNUHhtMlk1WTZ3U21uM2h2STF2OG9SaGtNbE54cmdfUFp1bTFueWE0ck1hZndZMGlOMzlnX0c5U3lyX2d1OEswLWdZOHg2R1FTTFg3RjZFaVN4TWJqUkUyYlN0NHpZT1RQM1gzSFZXUFlWbTlVZUdQbG9DbG9qd09MdE9KaTVMUGYxWFNOR1FUcWZYc1hjZmxNN1hGcUxaVkVDLUZ4bVZDQ1hVaWVQbmRLSko1TmhxaWhib2N1UjE0UQ?oc=5","date":"2026-04-07","type":"regulatory","source":"Stock Titan","summary":"Diabetic macular edema study on ILUVIEN is now in Ophthalmology - Stock Titan","headline":"Diabetic macular edema study on ILUVIEN is now in Ophthalmology","sentiment":"neutral"},{"date":"2026-04-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNM1dCYzJkRDlxNHVRcUtpN0dJQkVlNVVmNThjeFk5Ykh3N2tNRDc5RmlFTm9zOFRVVFpveG5mOVRxNGFQc3ByRUhVSFNzTlNIanE0S1QtdUJ3bnBucGZWSDBnZDhUTWNxV3JlSFV5Zm9KWVRGeExIdjg0NC1Ndm5lVUJiVXRXa1hFZklB?oc=5","date":"2026-03-31","type":"pipeline","source":"qz.com","summary":"ANI Pharmaceuticals 2026 Watchlist: Gout Sales Force and Rare Disease - qz.com","headline":"ANI Pharmaceuticals 2026 Watchlist: Gout Sales Force and Rare Disease","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-18","type":"pipeline","source":"simplywall.st","summary":"Is ANI Pharmaceuticals (ANIP) Pullback Hiding A Contradiction In Its Valuation Story - simplywall.st","headline":"Is ANI Pharmaceuticals (ANIP) Pullback Hiding A Contradiction In Its Valuation Story","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxNTDdqQkY5WkI5TmtVZ0o1dUw2dzdGRXBFVFlnY2syYmFGRC1HVTk0UVpOWVN3WTdKUU5kMkNLUEl2UVg4SDBwQ0JBRVBqaGFfWEE2YjhCQTQ0WnZTRUdGR3JpLThEY0JCdDVsa3B2SXVwQmRzQU1OYlFoNTZMRXMyMjFjXzl0UFRoSFFOa3M4bzZlSjNtNG1rdlN0VjBIbld5WDk3OHdIMUVGNHA0QzdLM2o1TzBkWllsQ1hVaVZxcjBQSUNJV0pUYldKX1gwSnVsUV90YzdfZWtKanpEOTUzUzRNVDRfUFlBdkltNHR3MA?oc=5","date":"2026-03-16","type":"deal","source":"MarketBeat","summary":"234,219 Shares in ANI Pharmaceuticals, Inc. $ANIP Acquired by Divisadero Street Capital Management LP - MarketBeat","headline":"234,219 Shares in ANI Pharmaceuticals, Inc. $ANIP Acquired by Divisadero Street Capital Management LP","sentiment":"neutral"},{"date":"2026-03-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxQOEh1d0FSV2lRQTg0ZmdaMlNYN2NHeXdnckJlbEZOU2xFSmgxeXNkdGx1aUUwOEJBSzJ3WnBwbk9tbGhqMVk5YkwxeFdfTDQtMHZOWFY1ZnR5WGY2MW12THp4YjRKOFhNLVpJUEtFaUJSWEhkaF96Nm8wQ0dvU3hObVlkVWpaRnFTUkxEV2pBNEFndFJNTU1VcXliTWtoS2pSWFZWN3ZRMmlRa3N2N0JjR2JrUl9vMkNCVEEwc0ZpUGI5TGFzaVBMd2k5aUhSbWE1cmU5LXZGTEpLTW05RzFVdzBn?oc=5","date":"2026-02-27","type":"earnings","source":"TradingView","summary":"ANI Pharmaceuticals (NASDAQ:ANIP) Beats Expectations in Strong Q4 CY2025, Stock Jumps 12.4% - TradingView","headline":"ANI Pharmaceuticals (NASDAQ:ANIP) Beats Expectations in Strong Q4 CY2025, Stock Jumps 12.4%","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNd0hRTHJ4NU1fWnh1emRzUWVkWjc2cmhuM3ZIdHFfT0MwZ09uMkZHYzA2a21VT1pCR2FUaG1IeFFZUVc3dDd5MVZMZmNtempoTWFmblpieXhEVnJKelRmdEx2ajZXN1djN0FhemlWSDJpSnJZeXZoV0ZIZXNqeHl0V01NMl9yMERWSnhnYW4wOEJXaG9M?oc=5","date":"2026-01-24","type":"pipeline","source":"Yahoo Finance","summary":"Assessing ANI Pharmaceuticals (ANIP) Valuation After Mixed Share Performance And Cortrophin Gel Growth Prospects - Yahoo Finance","headline":"Assessing ANI Pharmaceuticals (ANIP) Valuation After Mixed Share Performance And Cortrophin Gel Growth Prospects","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPZnp4Z3FwZ0hHQkpYOVEwWVdGRWR5cll0NDd5TlVoX1Bhb0FCaFlGS01qSlVLbVRYUE0xZUg4bjd0dzBuTmZSWWpBQWJkY2kxbEJHT1lxVEw3ZnpKdjFXZGd4cGw5cl9mWE1kZVFfYU1NNGxJMWZoRUE5ZzdfeHM1ck9PVElDNWM3anRr?oc=5","date":"2026-01-13","type":"pipeline","source":"Yahoo Finance","summary":"ANI Pharmaceuticals (ANIP) Stock Trades Down, Here Is Why - Yahoo Finance","headline":"ANI Pharmaceuticals (ANIP) Stock Trades Down, Here Is Why","sentiment":"neutral"}],"patents":[{"drugName":"Xanax","drugSlug":"alprazolam","patentNumber":"","type":"Patent Cliff","expiryDate":"2027-06-01","territory":"US","annualRevenue":100000000},{"drugName":"Lamictal","drugSlug":"lamotrigine","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":50000000},{"drugName":"Vancocin","drugSlug":"vancomycin","patentNumber":"11517609","type":"Method of Use","expiryDate":"2035-11-06","territory":"US","genericFilings":[]},{"drugName":"Vancocin","drugSlug":"vancomycin","patentNumber":"10188697","type":"Formulation","expiryDate":"2035-11-06","territory":"US","genericFilings":[]},{"drugName":"Vancocin","drugSlug":"vancomycin","patentNumber":"10039804","type":"Formulation","expiryDate":"2035-11-06","territory":"US","genericFilings":[]},{"drugName":"Vancocin","drugSlug":"vancomycin","patentNumber":"10849956","type":"Formulation","expiryDate":"2035-11-06","territory":"US","genericFilings":[]},{"drugName":"Vancocin","drugSlug":"vancomycin","patentNumber":"11000567","type":"Formulation","expiryDate":"2035-11-06","territory":"US","genericFilings":[]}],"drugCount":6,"phaseCounts":{"marketed":6},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Teva Pharmaceuticals","Endo International","Mallinckrodt Pharmaceuticals"],"therapeuticFocus":["Central Nervous System Disorders","Cardiovascular Diseases","Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":206547000,"revenuePeriod":"2019-12-31","revenueHistory":[{"value":206547000,"period":"2019-12-31"},{"value":47966000,"period":"2019-12-31"},{"value":51337000,"period":"2019-09-30"},{"value":54357000,"period":"2019-06-30"},{"value":52887000,"period":"2019-03-31"}],"grossProfit":542056000,"grossProfitHistory":[{"period":"2025-12-31","value":542056000},{"period":"2024-12-31","value":364166000},{"period":"2023-12-31","value":305303000},{"period":"2022-12-31","value":177600000}],"rdSpend":51664000,"rdSpendHistory":[{"period":"2025-12-31","value":51664000},{"period":"2024-12-31","value":44581000},{"period":"2023-12-31","value":34286000},{"period":"2022-12-31","value":22318000}],"sgaSpend":317745000,"operatingIncome":81230000,"operatingIncomeHistory":[{"period":"2025-12-31","value":81230000},{"period":"2024-12-31","value":2218000},{"period":"2023-12-31","value":49529000},{"period":"2022-12-31","value":-25734000}],"netIncome":78337000,"netIncomeHistory":[{"period":"2025-12-31","value":78337000},{"period":"2024-12-31","value":-18522000},{"period":"2023-12-31","value":18779000},{"period":"2022-12-31","value":-47896000}],"eps":3.32,"epsHistory":[{"period":"2025-12-31","value":3.32},{"period":"2024-12-31","value":-1.04},{"period":"2023-12-31","value":0.85},{"period":"2022-12-31","value":-3.05}],"cash":285585000,"cashHistory":[{"period":"2025-12-31","value":285585000},{"period":"2024-12-31","value":144861000},{"period":"2023-12-31","value":221121000},{"period":"2022-12-31","value":48228000}],"totalAssets":1440377000,"totalLiabilities":899653000,"totalDebt":617035000,"equity":540724000,"operatingCashflow":185225000,"operatingCashflowHistory":[{"period":"2025-12-31","value":185225000},{"period":"2024-12-31","value":64017000},{"period":"2023-12-31","value":118959000},{"period":"2022-12-31","value":-31203000}],"capex":-34321000,"capexHistory":[{"period":"2025-12-31","value":-34321000},{"period":"2024-12-31","value":-16953000},{"period":"2023-12-31","value":-18511000},{"period":"2022-12-31","value":-16455000}],"freeCashflow":150904000,"dividendsPaid":-1157000,"buybacks":-12209000,"employees":970,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":82790000,"ebit":35890000,"ebitda":58503000,"period":"2025-12-31","revenue":247060000,"epsBasic":1.24,"netIncome":27490000,"rdExpense":12261000,"epsDiluted":1.18,"grossProfit":146791000,"operatingIncome":29127000},{"sga":76656000,"ebit":38527000,"ebitda":61159000,"period":"2025-09-30","revenue":227813000,"epsBasic":1.19,"netIncome":26617000,"rdExpense":12304000,"epsDiluted":1.13,"grossProfit":134424000,"operatingIncome":22832000},{"sga":81771000,"ebit":15963000,"ebitda":39244000,"period":"2025-06-30","revenue":211371000,"epsBasic":0.37,"netIncome":8549000,"rdExpense":16535000,"epsDiluted":0.36,"grossProfit":136756000,"operatingIncome":15169000},{"sga":76528000,"ebit":25471000,"ebitda":48362000,"period":"2025-03-31","revenue":197122000,"epsBasic":0.7,"netIncome":15681000,"rdExpense":10564000,"epsDiluted":0.69,"grossProfit":124085000,"operatingIncome":14102000},{"sga":69719000,"ebit":-7747000,"ebitda":14853000,"period":"2024-12-31","revenue":190574000,"epsBasic":-0.55,"netIncome":-10276000,"rdExpense":16646000,"epsDiluted":-0.55,"grossProfit":110294000,"operatingIncome":1329000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":79.75,"previousClose":80.88,"fiftyTwoWeekHigh":99.5,"fiftyTwoWeekLow":56.71,"fiftyTwoWeekRange":"56.71 - 99.5","fiftyDayAverage":77.44,"twoHundredDayAverage":83.29,"beta":0.46,"enterpriseValue":2019178496,"forwardPE":7.4,"priceToBook":3.03,"priceToSales":1.96,"enterpriseToRevenue":2.19,"enterpriseToEbitda":10.23,"pegRatio":0,"ebitda":197379008,"ebitdaMargin":21.4,"freeCashflow":140259504,"operatingCashflow":208608992,"totalDebt":630209984,"debtToEquity":112.1,"currentRatio":3.12,"returnOnAssets":5,"returnOnEquity":18.3,"analystRating":"1.6 - Buy","recommendationKey":"buy","numberOfAnalysts":8,"targetMeanPrice":109.88,"targetHighPrice":124,"targetLowPrice":90,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":7.2,"institutionHeldPercent":101.7,"sharesOutstanding":22734618,"floatShares":19641626,"sharesShort":3562734,"shortRatio":10.78,"shortPercentOfFloat":15.6,"epsTrailing":3.91,"epsForward":10.71,"revenuePerShare":45.33,"bookValue":26.34,"officers":[{"age":47,"name":"Mr. Nikhil  Lalwani","title":"President, CEO & Director"},{"age":54,"name":"Mr. Stephen P. Carey","title":"Senior VP of Finance & CFO"},{"age":51,"name":"Ms. Meredith W. Cook J.D.","title":"Senior VP, General Counsel & Corporate Secretary"},{"age":53,"name":"Mr. Christopher K. Mutz","title":"Senior VP & Head of Rare Disease"},{"age":50,"name":"Mr. Ori  Gutwerg","title":"Senior Vice President of Generics"},{"age":57,"name":"Mr. Muthusamy  Shanmugam MS R.Ph.","title":"Head of R&D, COO of New Jersey Operations & Director"},{"age":null,"name":"Ms. Elizabeth  Powell J.D.","title":"Chief Compliance Officer & Head of Legal of Rare Disease"},{"age":49,"name":"Mr. Chad  Gassert","title":"Senior Vice President of Corporate Development & Strategy"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"http://www.biosantepharma.com/SEC-Filings.php","website":"https://www.anipharmaceuticals.com","phone":"218 634 3500"}}